A detailed history of Bank Of America Corp transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 159,773 shares of MRSN stock, worth $404,225. This represents 0.0% of its overall portfolio holdings.

Number of Shares
159,773
Previous 209,563 23.76%
Holding current value
$404,225
Previous $938,000 65.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.0 - $4.45 $99,580 - $221,565
-49,790 Reduced 23.76%
159,773 $321,000
Q1 2024

May 15, 2024

BUY
$2.16 - $5.94 $102,597 - $282,144
47,499 Added 29.31%
209,563 $938,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $2.34 $154,766 - $326,263
-139,429 Reduced 46.25%
162,064 $375,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $2.2 Million - $6.82 Million
-714,391 Reduced 70.32%
301,493 $991,000
Q1 2023

May 12, 2023

BUY
$4.0 - $7.02 $1.02 Million - $1.79 Million
255,161 Added 33.54%
1,015,884 $4.18 Million
Q4 2022

Feb 10, 2023

BUY
$5.65 - $7.86 $2.05 Million - $2.85 Million
363,077 Added 91.31%
760,723 $4.46 Million
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $1.58 Million - $2.73 Million
340,869 Added 600.36%
397,646 $2.69 Million
Q2 2022

Aug 12, 2022

BUY
$2.84 - $5.0 $63,252 - $111,360
22,272 Added 64.55%
56,777 $262,000
Q1 2022

May 16, 2022

SELL
$3.74 - $6.63 $31,199 - $55,307
-8,342 Reduced 19.47%
34,505 $138,000
Q4 2021

Feb 08, 2022

SELL
$5.48 - $9.86 $189,268 - $340,544
-34,538 Reduced 44.63%
42,847 $266,000
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $189,629 - $320,553
22,153 Added 40.11%
77,385 $730,000
Q2 2021

Sep 13, 2021

BUY
$13.28 - $18.07 $733,480 - $998,042
55,232 New
55,232 $750,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $246M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.